Regeneron Pharmaceuticals, Inc. (REGN)
NASDAQ: REGN · Real-Time Price · USD
699.54
-15.08 (-2.11%)
Dec 19, 2024, 10:39 AM EST - Market open
Regeneron Pharmaceuticals Employees
Regeneron Pharmaceuticals had 13,450 employees as of December 31, 2023. The number of employees increased by 1,599 or 13.49% compared to the previous year.
Employees
13,450
Change (1Y)
1,599
Growth (1Y)
13.49%
Revenue / Employee
$1,029,524
Profits / Employee
$346,059
Market Cap
75.29B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 13,450 | 1,599 | 13.49% |
Dec 31, 2022 | 11,851 | 1,483 | 14.30% |
Dec 31, 2021 | 10,368 | 1,245 | 13.65% |
Dec 31, 2020 | 9,123 | 1,023 | 12.63% |
Dec 31, 2019 | 8,100 | 700 | 9.46% |
Dec 31, 2018 | 7,400 | 1,200 | 19.35% |
Dec 31, 2017 | 6,200 | 800 | 14.81% |
Dec 31, 2016 | 5,400 | 1,100 | 25.58% |
Dec 31, 2015 | 4,300 | 1,375 | 47.01% |
Dec 31, 2014 | 2,925 | 585 | 25.00% |
Dec 31, 2013 | 2,340 | 390 | 20.00% |
Dec 31, 2012 | 1,950 | 246 | 14.44% |
Dec 31, 2011 | 1,704 | 309 | 22.15% |
Dec 31, 2010 | 1,395 | 366 | 35.57% |
Dec 31, 2009 | 1,029 | 110 | 11.97% |
Dec 31, 2008 | 919 | 237 | 34.75% |
Dec 31, 2007 | 682 | 109 | 19.02% |
Dec 31, 2006 | 573 | -15 | -2.55% |
Dec 31, 2005 | 588 | -142 | -19.45% |
Dec 31, 2004 | 730 | 86 | 13.35% |
Dec 31, 2003 | 644 | -25 | -3.74% |
Dec 31, 2002 | 669 | 94 | 16.35% |
Dec 31, 2001 | 575 | 84 | 17.11% |
Dec 31, 2000 | 491 | 54 | 12.36% |
Dec 31, 1999 | 437 | 66 | 17.79% |
Dec 31, 1998 | 371 | 101 | 37.41% |
Dec 31, 1997 | 270 | 27 | 11.11% |
Dec 31, 1996 | 243 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
Company Name | Employees |
---|---|
HCA Healthcare | 310,000 |
CVS Health | 300,000 |
Elevance Health | 104,900 |
Medtronic | 95,000 |
Becton, Dickinson and Company | 73,000 |
The Cigna Group | 72,500 |
GSK | 70,212 |
McKesson | 51,000 |
REGN News
- 3 hours ago - Regeneron to Advance Two Factor XI Antibodies into a Broad Phase 3 Program Following Positive Phase 2 Proof-of-concept Results - GlobeNewsWire
- 1 day ago - Regeneron Announces Presentation at the 43rd Annual J.P. Morgan Healthcare Conference - GlobeNewsWire
- 2 days ago - Regeneron Named to Dow Jones Sustainability World Index for Sixth Consecutive Year - GlobeNewsWire
- 9 days ago - Odronextamab ASH Presentations Underscore Impressive Potential in Earlier Lines of Treatment and Additional Types of Lymphoma - GlobeNewsWire
- 11 days ago - Novel Combination of Pozelimab and Cemdisiran (Poze-Cemdi) Achieved Greater Control of Intravascular Hemolysis in Patients with Paroxysmal Nocturnal Hemoglobinuria Compared to Ravulizumab - GlobeNewsWire
- 13 days ago - Regeneron Pharmaceuticals, Inc. (REGN) Piper Sandler 36th Annual Healthcare Conference (Transcript) - Seeking Alpha
- 14 days ago - Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Continues Investigation of Regeneron Pharmaceuticals, Inc. (REGN) on Behalf of Investors - GlobeNewsWire
- 16 days ago - Medigene Receives Milestone Payment from Regeneron Pharmaceuticals, Inc. - GlobeNewsWire